Cytarabine and Daunorubicin in Acute Myeloid Leukemia

Phase 1, open-label, single-arm trial of cytarabine and daunorubicin in acute myeloid leukemia (AML), sponsored by Wake Forest University Health Sciences. Primary endpoints: Number of Participants With Cardiac Toxicity, Defined as Reduction in LVEF of >= 10% Compared to Baseline LVEF and EF =< 50% on the Follow-up Scan, Assessed Using MRI at 3 months, Unexpected Toxicities (Exclude Hematologic and Infectious) >= Grade 3, as Measured by CTCAE v 4.0 at 30 days and 3 more. Started Nov 2016; status: completed.